Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas

Journal of Nuclear Medicine

Volumn 51, Issue 9, 2010, Pages 1439-1446

  Fagerholm, Veronica ^a   Mikkola, Kirsi K ^a   Ishizu, Tamiko ^a   Arponen, Eveliina ^a   Kauhanen, Saila ^a,b   Någren, Kjell ^a   Solin, Olof ^a   Nuutila, Pirjo ^a   Haaparanta, Merja ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

cell mass; Autoradiography; DTBZ; Pancreas; PET

Indexed keywords

CHLORPROMAZINE; DIHYDROTETRABENAZINE C 11; DIHYDROTETRABENAZINE H 3; GLUCOSE; HALOPERIDOL; KETANSERIN; LOBELINE; RADIOPHARMACEUTICAL AGENT; RESERPINE; STREPTOZOCIN; TETRABENAZINE; TRITIUM; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; DIHYDROTETRABENAZINE; DRUG DERIVATIVE; TRACER; VESICULAR MONOAMINE TRANSPORTER;

ADRENAL MEDULLA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING ASSAY; BLOOD SAMPLING; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG UPTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJECTION; MALE; METHYLATION; NONHUMAN; PANCREAS ISLET CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; TISSUE SECTION; ANIMAL; ANTIBODY SPECIFICITY; BINDING COMPETITION; CATTLE; DIABETES MELLITUS; FEMALE; METABOLISM; MIDDLE AGED; PANCREAS ISLET; PROTEIN BINDING;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; CATTLE; DIABETES MELLITUS; FEMALE; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; ORGAN SPECIFICITY; PROTEIN BINDING; RADIOACTIVE TRACERS; RATS; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77957059546     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.074492     Document Type: Article

References (26)

1. 18F]-DOPA positron emission tomography. Diabetes. 2006;55:13-18.
2. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237-1244.
3. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:213-227. (Pubitemid 40347812)
4. Koopmans KP, Neels ON, Kema IP, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71:199-213.
5. + toxicity encodes a vesicular amine transporter. Cell. 1992;70:539-551.
6. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA. 1992;89:10993-10997.
7. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem. 1994;269:7231-7237.
8. Erickson JD, Schäfer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA. 1996;93:5166-5171.
9. Anlauf M, Eissele R, Schäfer MK, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003; 51:1027-1040.
10. Maffei A, Liu Z, Witkowski P, et al. Identification of tissue-restricted transcripts in human islets. Endocrinology. 2004;145:4513-4521.
11. 3H] dihydrotetrabenazine. Proc Natl Acad Sci USA. 1983;80:584-588.
12. Efange SM. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 2000;14:2401-2413.
13. Souza F, Simpson N, Raffo A, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest. 2006;116:1506-1513.
14. 11C]DTBZ. Nucl Med Biol. 2006;33:855-864.
15. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009;50:382-389.
16. Freeby M, Goland R, Ichise M, Maffei A, Leibel R, Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab. 2008;10(suppl. 4):98-108.
17. Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med. 2008;86:5-16.
18. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
19. 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med. 1999;40:283-289.
20. Darchen F, Scherman D, Laduron PM, Henry JP. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol. 1988;33:672-677.
21. 3H]dopamine from rat striatal synaptic vesicles: comparison with D-amphetamine. J Neurochem. 1998;71:258-265.
22. 18F epoxide derivative of tetrabenazine. Nucl Med Biol. 2008;35:825-837.
23. 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008;49:1171-1176.
24. Saisho Y, Harris PE, Butler AE, et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol. 2008;39:543-551.
25. Mei Q, Mundinger TO, Lernmark A, Taborsky GJ Jr. Early, selective, and marked loss of sympathetic nerves from the islets of BioBreeder diabetic rats. Diabetes. 2002;51:2997-3002.
26. 11C] dihydrotetrabenazine positron emission tomography scanning in assessing beta-cell performance after sleeve gastrectomy and duodenal-jejunal bypass. Surgery. 2010;147:303-309.